Detalles de la búsqueda
1.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
N Engl J Med
; 384(3): 229-237, 2021 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33113295
2.
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
N Engl J Med
; 385(15): 1382-1392, 2021 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34260849
3.
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Clin Infect Dis
; 75(1): e440-e449, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34718468
4.
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA
; 325(7): 632-644, 2021 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33475701
5.
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
JAMA
; 326(1): 46-55, 2021 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081073
6.
Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2).
Trials
; 22(1): 726, 2021 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34674750
Resultados
1 -
6
de 6
1
Próxima >
>>